A detailed history of Marshall Wace, LLP transactions in Rezolute, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 1,128,553 shares of RZLT stock, worth $4.97 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,128,553
Previous 1,047,230 7.77%
Holding current value
$4.97 Million
Previous $4.5 Million 21.54%
% of portfolio
0.01%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.13 - $5.31 $335,863 - $431,825
81,323 Added 7.77%
1,128,553 $5.47 Million
Q2 2024

Aug 14, 2024

BUY
$2.29 - $5.79 $2.4 Million - $6.06 Million
1,047,230 New
1,047,230 $4.5 Million

Others Institutions Holding RZLT

About Rezolute, Inc.


  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $171M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.